Expect Equity LLC Invests $2.09 Million in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Expect Equity LLC bought a new position in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 92,105 shares of the life sciences company's stock, valued at approximately $2,089,000. Integra LifeSciences comprises 2.2% of Expect Equity LLC's portfolio, making the stock its 24th biggest position. Expect Equity LLC owned about 0.12% of Integra LifeSciences at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the business. Capital Research Global Investors lifted its position in Integra LifeSciences by 7.4% during the fourth quarter. Capital Research Global Investors now owns 1,400,559 shares of the life sciences company's stock valued at $31,765,000 after purchasing an additional 95,944 shares during the last quarter. Lord Abbett & CO. LLC raised its stake in shares of Integra LifeSciences by 86.8% in the fourth quarter. Lord Abbett & CO. LLC now owns 1,332,031 shares of the life sciences company's stock valued at $30,210,000 after acquiring an additional 618,773 shares during the period. Charles Schwab Investment Management Inc. raised its stake in shares of Integra LifeSciences by 10.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,047,573 shares of the life sciences company's stock valued at $23,759,000 after acquiring an additional 103,291 shares during the period. Northern Trust Corp raised its stake in shares of Integra LifeSciences by 9.9% in the fourth quarter. Northern Trust Corp now owns 892,425 shares of the life sciences company's stock valued at $20,240,000 after acquiring an additional 80,090 shares during the period. Finally, Principal Financial Group Inc. raised its stake in shares of Integra LifeSciences by 5.5% in the fourth quarter. Principal Financial Group Inc. now owns 423,432 shares of the life sciences company's stock valued at $9,603,000 after acquiring an additional 22,000 shares during the period. Institutional investors own 84.78% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on IART shares. Wells Fargo & Company reduced their target price on shares of Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating on the stock in a research note on Tuesday, May 6th. Argus upgraded shares of Integra LifeSciences from a "hold" rating to a "buy" rating in a report on Monday, March 31st. JMP Securities lowered their target price on shares of Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating for the company in a research note on Friday, May 9th. Truist Financial lowered their target price on shares of Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating for the company in a research note on Friday, April 11th. Finally, JPMorgan Chase & Co. reduced their price target on shares of Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating for the company in a research report on Tuesday, May 6th. Four analysts have rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $18.63.

Integra LifeSciences Price Performance

NASDAQ IART traded down $0.65 on Wednesday, hitting $12.86. The company had a trading volume of 648,995 shares, compared to its average volume of 1,043,344. The company has a market capitalization of $999.38 million, a PE ratio of -142.87, a PEG ratio of 0.73 and a beta of 1.27. The company's fifty day moving average price is $18.59 and its 200-day moving average price is $21.81. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.20 and a quick ratio of 0.73. Integra LifeSciences Holdings Co. has a 12-month low of $11.60 and a 12-month high of $32.66.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last released its earnings results on Monday, May 5th. The life sciences company reported $0.41 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.43 by ($0.02). Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The business had revenue of $382.65 million for the quarter, compared to analysts' expectations of $381.17 million. During the same period in the previous year, the company earned $0.55 EPS. Integra LifeSciences's quarterly revenue was up 3.7% compared to the same quarter last year. As a group, analysts predict that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current year.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.